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Abstract
Background: Studies indicate that thymidylate synthase (TS) expression, p53 and mismatch repair
status have potential to influence colorectal cancer (CRC) outcome. There is, however, little data
on the inter-relationship between these three markers. We sought to investigate whether
relationships exist between these markers that might contribute to CRC phenotypes.
Methods: Four hundred and forty-one stage I-III CRCs were investigated. p53 status and TS
expression were assessed by standard immunohistochemistry methods. Mismatch repair status was
determined by assessment of microsatellite instability (MSI) using radiolabelled microsatellite
genotyping.
Results: 244 tumours (55%) over-expressed p53, and 259 (58%) expressed high TS levels. 65
tumours (15%) had MSI. A significant relationship between p53 over-expression and high TS
expression was observed (p = 0.01). This was independent of MSI status. A highly significant inverse
relationship between MSI and p53 status was observed (p = 0.001). No relationship was seen
between MSI status and TS expression (p = 0.59).
Conclusion: Relationships exist between p53 status and TS expression, and MSI and p53 status.
These inter-relationships may contribute to the clinical phenotype of CRCs associated with each
of the molecular markers. High TS expression is unlikely to account for the clinical behaviour of
CRCs with MSI.
Background
Colorectal cancer (CRC) is one of the commonest malig-
nancies of developed countries [1], with approximately
19,000 and 160,000 new cases in the UK and US, respec-
tively, each year, and around 500,000 new cases world-
wide [2,3]. CRC tumourigenesis is a multi-step phenome-
non, typified by a series of genomic events that parallel
development of invasive malignancy from normal epithe-
lium through formation of pre-malignant adenomas [4].
Whilst most (~85%) CRCs develop through the chromo-
somal instability pathway, in which adenoma formation
is typified by loss of APC function, and development of
invasive malignancy by TP53  mutation [4], a smaller
number (~15%) develop as a consequence of mismatch
repair (MMR) deficiency. These tumours are characterised
by high frequency microsatellite instability (MSI), proxi-
mal colonic distribution, poor differentiation, mucinous
appearance, and lymphocytic infiltration [5]. Addition-
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ally, these tumours tend to retain the native diploid state
[5]. By contrast, chromosomally unstable tumours tend to
be aneuploid and have no site predilection [6].
Several studies have demonstrated that tumour molecular
phenotype is a determinant of CRC prognosis [7-9].
Although many markers of prognosis have been investi-
gated in recent years, the most promising to date are mis-
match repair status, thymidylate synthase (TS) expression
level, and p53 status.
Tumours developing through the mismatch repair path-
way are characterised by loss of mismatch repair gene
function (primarily hMLH1), through either mutation or
more commonly, epigenetic change [5]. This results in
somatic hypermutability most pronounced at short tan-
dem repeat sequences such as microsatellites, termed mic-
rosatellite instability (MSI), readily detectable by the
presence/absence of novel alleles or the shortening of at
least 2–3 repeat units by electrophoresis. Several studies of
clinical datasets have indicated that CRCs with MSI are
associated with improved survival [10]. However, in vitro
data has indicated that these tumours are paradoxically
characterised by 5FU chemoresistance [11,12]. Although
the mechanism for these observations remain unclear, the
notion that fluoropyrimidine sensitivity might be modu-
lated through either TS expression or p53 mutation is
plausible [13]. Thymidylate synthase (TS) is a major pro-
tein involved in CRC development and outcome. As well
as providing the sole intracellular source of thymidine for
DNA synthesis [14], TS is also a target for a number of
drugs used for CRC treatment, including 5-fluorouracil
(5FU), whose mechanism of action is primarily mediated
through competitive TS inhibition. Thymidylate synthase
expression has been shown to be a key determinant of
5FU resistance in vitro [14,15] and several patient series
have confirmed poorer outcomes in those with tumours
expressing high TS levels [16]. Mutation in the tumour
suppressor TP53 has also been associated with chemore-
sistance and poorer survival in CRC [17,18]. TP53 maps to
chromosome 17p13.1 [19] and is one of the commonest
genes mutated in CRC, encoding a transcription factor
(p53) critically involved in control of cell cycle, apoptosis,
and carcinogenesis [20-25].
Whilst each of these markers impact on CRC prognosis,
the inter-relationship between each has been the subject
of few studies. Hence, the contribution to the clinical
behaviour of CRCs associated with either p53, TS or mis-
match repair status of any such inter-relationship is
unclear. Here we report analysis of the largest series of




Four hundred and forty-one paired paraffin-embedded
formalin fixed tissue blocks (one tumour tissue and one
normal tissue) from patients with stage I-III CRC collected
at the time of potentially curative surgery were assessed.
The study was conducted in accordance with the tenets of
the Declaration of Helsinki.
Fifteen-micron sections of formalin-fixed paraffin embed-
ded tumours were cut onto double-sided clear adhesive
tape on glass slides. Regions of ≥ 70% tumour were micro-
dissected after light staining with toluidine blue. Ten-
micron whole sections of normal mucosa from a separate
paired block of normal colorectal mucosa from each
patient were provided as a source of germline DNA extrac-
tion. DNA was extracted using standard commercially
available methods (Qiagen, West Sussex, UK) and geno-
typing was performed at the highly sensitive and specific
mononucleotide microsatellite locus BAT26 [26,27]. In
cases where no paired normal tissue was available,
tumour DNA was genotyped alone. Target DNA
sequences were amplified using 32P end-labelled primers.
Mismatch repair status was assigned as MSI or microsatel-
lite stable (MSS) by presence or absence of novel alleles or
the shortening of at least 2–3 repeat units at autoradiogra-
phy. Genotyping was performed at least twice per sample.
Only tumours with unambiguous genotypes were
assigned MSI status.
p53 and TS evaluation
Three micron sections from a representative part of the
primary tumour were cut onto silane coated glass slides
and assessed for TS and p53 expression by the avidin-
biotin complex immunohistochemical technique
(Vectastain Elite ABC kit, Vector Laboratories Inc, Burlin-
game, CA, USA) [28]. Negative and positive control slides
were included in each staining run. Primary antibody was
replaced with phosphate buffered saline, pH 7.6/0.1% (v/
v) Tween solution for negative controls, and tumour sec-
tions known to stain heavily for target antigens were used
for positive controls.
Tumour sections were deparaffinized in Histoclear
(National Diagnostics, Hull, UK) and hydrated in decreas-
ing concentrations of ethanol. Endogenous peroxidase
activity was quenched with 5% hydrogen peroxide in
methanol for 20 minutes. Antigen retrieval was required
for p53 only and was by a microwave oven-based method.
Specifically, sections were incubated in boiling 10 mmol/
L citric acid buffer (pH 6.0) for 10 minutes and then
cooled in running water. For both TS and p53, non-spe-
cific background staining was blocked with 20% goat
serum for 20 minutes. Sections were then incubated with
appropriate primary antibodies at a 1:100 dilution, in aBMC Cancer 2006, 6:150 http://www.biomedcentral.com/1471-2407/6/150
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humidified chamber at room temperature for 60 minutes,
using either a validated rabbit polyclonal antibody to
recombinant human TS [29], or an anti-p53 mouse mon-
oclonal (clone DO-7, Dako Corp, Denmark). After rins-
ing, a biotinylated anti-rabbit secondary antibody was
applied for 30 minutes followed by further washing, and
avidin-biotin-peroxidase complexes (Vectastain Elite ABC
kit; Vector Laboratories Inc, Burlingame, CA, USA).
Immunostaining was developed by applying freshly pre-
pared 0.05% 3, 3'-diaminobenzidine tetrahydrochloride
(Vectastain Elite ABC kit, Vector laboratories). Sections
were counterstained in Mayer's Haematoxylin (Sigma
Chemical Co., St Louis, MO, USA), dehydrated in a series
of ethanols, cleared in Histoclear (National Diagnostics,
Hull, UK) and mounted with glass coverslips using DePeX
(BDH, Poole, UK).
Immunohistochemistry evaluation
All slides were randomly allocated for independent assess-
ment by two observers (RSH and SP), blinded to marker
status. TS expression was assessed using the commonest
reported method; a semiquantative grading of tumour tis-
sue for chromagen intensity from 0 to 3, with the highest
tumour staining detected as the reference for classifica-
tion. Grades 0 and 1, representing none and minimal
staining respectively, were defined as the "low" expression
group, whereas grades 2 and 3 were defined as the "high"
expression group. p53 immunoreactivity was dichot-
omised into positive or negative based on staining of
malignant nuclei, with a threshold of 10%.
Level of scoring agreement between the two observers was
recorded. In cases of disagreement, marker status was dis-
cussed and determined by consensus.
Statistical analysis
All statistical manipulations were preformed using STATA
(Version 7, Stata Corp. TX77840, USA). Relationships
between TS, p53 expression, and MSI status were assessed
with Fisher's exact test, stratified by relevant marker.
Results
Tumour phenotypes
Genotype data was available from all 441 specimens.
Sixty-five (15%) tumours demonstrated MSI, whereas 376
had MSS. Figure 1 shows representative tumour geno-
types, with two examples of MSI.
One quarter of the tumours stained for TS with grade 3
(101, 23%) or grade 0 (15, 3%) levels of chromagen
intensity, whilst three-quarters stained with either grade 1
(167, 38%) or grade 2 (158, 36%) intensity. When dichot-
omised into high and low levels of TS expression, just over
half of the samples expressed high TS levels (259, 59%),
with the remainder having low-level expression (182,
41%). Just over half demonstrated p53 over-expression
(244, 55%), with the remainder showing neither over-
expression nor staining (197, 45%). Figures 2 and 3 show
representative sections stained for TS and p53, respec-
tively, demonstrating levels of chromagen intensity
required to allocate expression status.
Inter-relationship between p53, TS, and mismatch repair 
status
A significant association between p53 status and TS chro-
magen intensity was observed (p = 0.01). This was main-
tained when dichotomising TS expression into high and
low groups. Specifically, tumours with p53 over-expres-
sion were significantly associated with high TS levels (p =
0.005, Table 1). When stratified by MSI status, a relation-
ship between p53 status and TS level was again observed
(p = 0.005), with tumours over-expressing p53 (p53 pos-
itive) tending to express high TS levels. This relationship
was maintained in both subsets of tumours with MSS (p =
0.01, Table 1), and MSI (p = 0.30, Table 1). Although this
relationship did not reach formal statistical significance in
MSI tumours, this was likely due to the small numbers of
tumours assessed, since an over-representation of p53
positive tumours with high TS levels was again observed.
As expected, a highly significant inverse relationship
between mismatch repair status and p53 status was
Representative examples of microsatellite instability (MSI) Figure 1
Representative examples of microsatellite instability (MSI). 
Somatic (T lanes) and paired germline (N lanes) genotypes at 
the microsatellite marker BAT26 detected by autoradiogra-
phy in 5 normal/normal pairs are shown. New somatic alleles 
(lanes T) (tumours 2 and 4) compared to germline genotypes 
(lanes N), as indicated by the arrows, are indicative of MSI.
NN NN TT TT T N
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observed; MSI tumours tending to be p53 negative (p =
0.001, Table 2). This was maintained and not influenced
by TS status (Table 2).
No relationship was observed between mismatch repair
status and TS level (p = 0.59, Table 3) and p53 status did
not impact on these findings (Table 3).
In order to exclude any bias that may have resulted from
erroneous classification, we reassessed p53 status using
thresholds of 5% and 15%. This resulted in no reclassifi-
cation, and therefore no change in associations. Our
results were further re-analysed using the Pearson χ2 test.
All significant and non-significant associations were
maintained. Our results have therefore been reported
using the Fisher test, which gives the exact p value, rather
than the asymptotic value calculated by the χ2 test.
Discussion
We have investigated the relationship between MSI, TS
and p53 status using standard genotyping and immuno-
histochemical methods in early stage CRC. Although only
loosely correlating with TP53 mutation, p53 nuclear over-
expression detected by IHC has been found to be a marker
of worse prognosis in many previously published analyses
of CRC datasets [21,30,31]. Our results indicate a highly
significant association between p53 status and TS expres-
sion, with CRCs expressing high TS levels more likely to
over-express p53, regardless of MSI status.
In normal cells, regulation of both TS and p53 are inde-
pendently tightly controlled. In addition to it's role in
enzyme catalysis, TS also functions as a RNA binding pro-
tein [32,33], regulating it's own expression by a negative
autoregulatory mechanism [33,34], as well as binding to
it's own RNA, to form TS-ribonucleoprotein complexes
with several RNA species including c-myc and TP53 [35].
Although in vitro data indicates that p53 and TS have the
ability to regulate each-other in non-malignant cells
[32,33,36], evidence for a relationship in CRC has been
conflicting, with some studies reporting that TS negatively
regulates p53 expression [37], whilst others have shown
no such relationship [38,39]. In addition, the potential
for wild-type p53 to regulate TS expression has also been
demonstrated using a luciferase-based system, which
showed that p53 expression can inhibit TYMS promoter
activity [40]. These results are, however, based on in vitro
analysis, and no studies have characterised the role of
Immunohistochemical analysis of tumours for p53 (a) p53  over-expression, (b) no p53 over-expression Figure 3
Immunohistochemical analysis of tumours for p53 (a) p53 
over-expression, (b) no p53 over-expression.
A)
B)
Immunohistochemical analysis of tumours for thymidylate  synthase (TS) showing (a) high level, and (b) low level TS  expression Figure 2
Immunohistochemical analysis of tumours for thymidylate 
synthase (TS) showing (a) high level, and (b) low level TS 
expression.
A) 
B) BMC Cancer 2006, 6:150 http://www.biomedcentral.com/1471-2407/6/150
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mutant p53 or whether aberrant mismatch repair impacts
on the relationship. Our results suggest a relationship
between TP53 status and TS expression implying that the
poor prognosis and chemoresistance observed in studies
of CRC patients with either high TS expression or TP53
mutation/p53 over-expression, may have been impacted
on by either co-variate.
A number of potential mechanisms may account for our
findings. TP53 mutation is associated with loss of tran-
scriptional activity control resulting in up- or down-regu-
lation of downstream p53 effectors. Thus, inactive p53
might disinhibit an inhibitory role of p53 on TS expres-
sion. Alternatively, according to the gain-of-function par-
adigm [41], mutant p53 might acquire novel activities
that promote cell growth and survival [42], perhaps
through enhanced TS expression. An example of the latter
case is the 273 Arg-His mutation, which has strong trans-
activating activity [43]. Although the role of this specific
mutation in regulating TS expression is unknown, it is fea-
sible that specific p53 mutations retain transcriptional
regulatory activity, which may be partially responsible for
control of transcriptional activity of proteins such as TS.
Supporting this, Lenz et al. investigated the relationship
Table 2: Relationship between p53 expression and microsatellite instability status, stratified by TS expression.
TS status p53 status MSI status
MSS MSI Total
All tumours + 221 23 244
- 155 42 197
Total 376 65 441*
TS low level tumours + 78 8 86
- 75 21 96
Total 153 29 182**
TS high level tumours + 143 15 158
- 80 21 101
Total 223 36 259***
*p = 0.001; **p = 0.03; ***p = 0.02; MSS, microsatellite stable; MSI, microsatellite instability; TS, thymidylate synthase
Table 1: Relationship between TS and p53 expression, stratified by microsatellite instability status.
MSI status p53 status TS status
Low High Total
All tumours + 86 158 244
- 96 101 197
Total 182 259 441*
MSI tumours + 81 5 2 3
- 21 21 42
Total 29 36 65**
MSS tumours + 78 143 221
- 75 80 155
Total 153 80 376***
*p = 0.005; **p = 0.30; ***p = 0.01; MSS, microsatellite stable; MSI, microsatellite instability; TS, thymidylate synthaseBMC Cancer 2006, 6:150 http://www.biomedcentral.com/1471-2407/6/150
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between TP53 mutation and TS expression in a series of
36 CRCs and demonstrated that CRCs with p53 muta-
tions affecting the zinc-binding domains had higher TS
expression than those with mutation outside these
domains [44]. Zinc domains are involved in direct DNA
contact, protein stabilization, and structural activity, indi-
cating that these mutations may have a severe impact on
the transcriptional activity of p53.
Nine other studies have investigated the relationship
between p53 and TS expression, based on immunohisto-
chemistry, using p53 over-expression as a surrogate of
TP53  mutation [8,45-52]. However, most have been
based on small sample sizes (median 66, range 22[51]–
691[48]). Our results are consistent with four [44-46,50]
of these studies, which also demonstrated a relationship
between p53 and TS expression. Moreover, our study is
the only one to assess this relationship stratified by MSI
status. The relationship between p53 and TS was observed
both in tumours with MSI and those with MSS, implying
that aberrant mismatch repair is unlikely to impact on any
mechanism relating p53 to TS expression. However, given
the small number of samples with MSI, this cannot be
entirely excluded.
As expected a highly significant inverse relationship
between p53 status and MSI was observed. This relation-
ship was independent of TS status, observed in both
tumours expressing low and high TS levels (p ≤ 0.03), and
is consistent with the concept that most CRCs develop
either along the chromosomal instability pathway associ-
ated with TP53 mutation and MSS tumours or the aber-
rant mismatch repair pathway associated with wild-type
p53 and MSI tumours [53-56]. This association may also
explain why tumours with MSI seem to have an improved
prognosis compared to those with intact mismatch repair.
However, we demonstrated no relationship between MSI
and TS status. This finding was independent of p53 status.
Whilst the precise mechanisms by which cells with MSI
seem resistant to 5FU in vitro has been poorly defined, Ric-
ciardiello et al. [57] have suggested that this may, in part,
be due to TS over-expression TS. In their analysis of 192
CRCs the authors demonstrated an association between
CRCs with MSI and high TS expression [57]. This observa-
tion was, however, contrary to an earlier study based on
an analysis of 53 CRCs, which also observed no relation-
ship between TS expression and the MSI phenotype [58].
Moreover, the study by Ricciardiello et al. [57] was based
on only 24 CRCs with MSI and the rate of high TS expres-
sion in their study was at the lower end of that previously
reported (21%) [16] and may have biased findings. Our
data, based on a sample size over two times larger, pre-
cludes at least a 16% difference between MMR status and
high TS expression at the 5% threshold, with 90% power.
Our results provide little evidence that TS expression plays
a major role in defining chemoresistance in microsatellite
unstable CRCs, but gives support to previous reports of an
inverse relationship between MSI and p53 status. In addi-
tion, we demonstrated that TS expression is related to p53
status, and this relationship may in part account for the
poorer prognosis and relative chemoresistance seen in
these tumours.
Conclusion
Relationships exist between TS expression and p53 status,
and MSI and p53 status in CRC that may account for the
clinical phenotypes of these tumours. High TS expression
Table 3: Relationship between microsatellite instability status and TS expression, stratified by p53 expression.
p53 status MSI status TS status
Low High Total
All tumours MSS 153 223 376
MSI 29 36 65
Total 182 259 441*
p53 negative tumours MSS 75 80 155
MSI 21 21 42
Total 96 101 197**
p53 positive tumours MSS 78 143 221
MSI 81 5 2 3
Total 86 158 244***
*p = 0.59; **p = 0.86; ***p = 1.0; MSS, microsatellite stable; MSI, microsatellite instability; TS, thymidylate synthaseBMC Cancer 2006, 6:150 http://www.biomedcentral.com/1471-2407/6/150
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is unlikely to play a major role in the clinical behaviour of
CRCs characterised by MMR deficiency.
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